Histological Samples News Today

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 2, 2024--

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If...

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting ...

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 16, 2023--

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...

* Results support potential for a new treatment option that builds on the benefit of first-line standard of care Tagrisso monotherapy Positive high-level results from the FLAURA2 Phase III trial... | May 17, 2023

Results support potential for a new treatment option that builds on the benefit of first-line standard of care TAGRISSO monotherapy ... | May 17, 2023

Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease

Investegate announcements from AstraZeneca PLC, Tagrisso approved in Japan for early lung cancer